Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $17.57

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.57.

Several analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, May 10th. UBS Group decreased their target price on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price objective for the company. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, May 10th. Finally, Guggenheim raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, May 14th.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 5.0% during the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after purchasing an additional 1,360,613 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Amicus Therapeutics by 1.3% during the 4th quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after purchasing an additional 364,539 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 101.9% during the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock worth $215,546,000 after purchasing an additional 7,666,335 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after purchasing an additional 2,307,385 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Amicus Therapeutics by 11.0% during the 3rd quarter. American Century Companies Inc. now owns 4,343,870 shares of the biopharmaceutical company’s stock worth $52,821,000 after purchasing an additional 429,257 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.80 on Friday. The company’s 50 day moving average price is $9.96 and its 200 day moving average price is $11.68. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a market capitalization of $2.90 billion, a PE ratio of -20.00 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a quick ratio of 2.61 and a current ratio of 3.03.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. The firm had revenue of $110.40 million for the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The firm’s revenue was up 27.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.18) earnings per share. Research analysts expect that Amicus Therapeutics will post -0.12 EPS for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.